AG0302-COVID‑19
AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3]This candidate followed a previous one called AG0301-COVID‑19.[4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Routes of administration | Intramuscular, Intradermal[1] |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
References
- "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 August 2021. Retrieved 6 October 2021.
- "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. 3 December 2020. Retrieved 11 March 2021.
- "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 8 December 2020. Retrieved 11 March 2021.
- "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.